Nevertheless, plaque stability from the treated and untreated group remained unchanged, characterized by similar VSMC and collagen content, suggesting that IL-33 treatment decreases atherosclerosis plaque size without affecting plaque stability (Table 3) (109). This evidence concerns the gene IL33 and atherosclerosis.